Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zap away dry eye? device uses electrical fields to soothe discomfort

NCT ID NCT06955806

Symptom relief Sponsor: The Hong Kong Polytechnic University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a device called Rexon-Eye that uses gentle electrical pulses to treat dry eye disease. Thirty adults aged 18 to 40 will receive either real or sham treatment once a week for four weeks. Researchers will check if symptoms improve and analyze tear samples to understand how the therapy works at a molecular level.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rexon-Eye device (QMR electrotherapy)
What this could lead to
If it works, this could offer a non-drug, non-invasive option to relieve dry eye discomfort and improve tear film stability.
What could go wrong
This is a small, early-stage study with only 30 people, so results may not apply to everyone. The sham control group helps, but the effect may be modest or temporary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * aged 18 to 40 years old * with habitual or best corrected visual acuity better than or equal to 6/9 * diagnosed as dry eye disease according to OSDI score (13 or above) and at least one positive result from dry eye assessment. Exclusion Criteria: * history of ocular inflammation, trauma or surgery within 6 months * long-term ocular medications * current dry eye treatment * uncontrolled, newly diagnosed systemic diseases * with modified long-term medications within 6 months that are known to affect tear profile * carrying active implantable devices (e.g., pacemakers and hearing aids)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dry eye disease (DED) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dry eye disease (DED)

Contacts and locations

Locations

  • The Hong Kong Polytechnic University

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.